PYXS
NASDAQPyxis Oncology Inc.
Price$2.59+0.27 (+11.23%)
01:30 PM02:45 PM
News · 26 weeks28-54%
2025-11-092026-05-03
Mix2090d
- Insider9(45%)
- SEC Filings6(30%)
- Other2(10%)
- Leadership2(10%)
- Analyst1(5%)
Latest news
25 items- PRPyxis Oncology Appoints Nelson Azoulay as Chief Business OfficerBOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer. Mr. Azoulay joins Pyxis Oncology with more than 15 years of experience in corporate strategy, business development, and value-creating transactions across the biopharma industry, including deep antibody-drug conjugate (ADC) experience. In his role, he will lead corporate development strategy and pursue strategic opportunities to advance MICVO, the Company's lead clinical asset. "We're excited to welcome Nelson to Pyxis Oncology," said Tom Ci
- ANALYSTWedbush initiated coverage on Pyxis Oncology with a new price targetWedbush initiated coverage of Pyxis Oncology with a rating of Outperform and set a new price target of $6.00
- SECSEC Form DEFA14A filed by Pyxis Oncology Inc.DEFA14A - Pyxis Oncology, Inc. (0001782223) (Filer)
- SECSEC Form DEF 14A filed by Pyxis Oncology Inc.DEF 14A - Pyxis Oncology, Inc. (0001782223) (Filer)
- SECAmendment: Pyxis Oncology Inc. filed SEC Form 8-K: Leadership Update8-K/A - Pyxis Oncology, Inc. (0001782223) (Filer)
- PRPyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment in a syngeneic preclinical model of HNSCC toward a more favorable immune-permissive environment for immunotherapy maMICVO in combination with anti-mouse PD-1 worked synergistically to produce greater anti-tumor activity compared with either treatment alone in an immune-refractory syngeneic preclinical model of HNSCC Preclinical findings support the ongoing clinical development of MICVO as both monotherapy and in combination with pembrolizumab for R/M HNSCC BOSTON, April 17, 2026 (GLOBE NEWSWIR
- INSIDERSEC Form 4 filed by Dupont Jakob4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- INSIDERSEC Form 4 filed by Wadhane Jitendra4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- INSIDERSEC Form 4 filed by Flavin John L4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- INSIDERSEC Form 4 filed by Metzger Michael A4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- INSIDERSEC Form 4 filed by Lewis-Hall Freda C4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- INSIDERSEC Form 4 filed by Cline Darren S4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- INSIDERSEC Form 4 filed by Humphrey Rachel4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- INSIDERSEC Form 4 filed by Palani Santhosh4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- INSIDERSEC Form 4 filed by Humphrey Rachel4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- SECSEC Form S-8 filed by Pyxis Oncology Inc.S-8 - Pyxis Oncology, Inc. (0001782223) (Filer)
- SECSEC Form 10-K filed by Pyxis Oncology Inc.10-K - Pyxis Oncology, Inc. (0001782223) (Filer)
- SECPyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
- PRPyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsCompleted target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTO
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pyxis Oncology Inc.SCHEDULE 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)
- SECPyxis Oncology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
- INSIDERSEC Form 4 filed by Interim CEO Civik Thomas4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- PRPyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program ContinuityBOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With
- PRThe $225B Precision Sprint: How Big Pharma is Beating the $170B Patent CliffVANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026
- SECPyxis Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
PYXS FAQ
7 questionsWhat does Pyxis Oncology Inc. do?
Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC...Where does PYXS stock trade?
Pyxis Oncology Inc. (PYXS) is listed on NASDAQ.What sector and industry is PYXS in?
Pyxis Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pyxis Oncology Inc. go public?
Pyxis Oncology Inc. (PYXS) completed its IPO in 2021.What are analysts saying about PYXS?
Pyxis Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $600.00 price target on 2026-05-05. Recent price targets range from $500.00 to $1300.00.What companies are similar to PYXS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare PYXS side-by-side with any of them on Quantisnow.How can I track PYXS on Quantisnow?
Quantisnow aggregates Pyxis Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PYXS to receive live email and push alerts on every new disclosure.